Immunoqure Ag

King's College London

Yale University

Gammadelta Therapeutics Ltd

Transimmune Ag

Cancer Research Technology Limited

The Francis Crick Institute Limited

Adrian Hayday

Annalisa Macagno

Kai Krohn

Kai Kisand

Mike Rothe

Shimobi Onuoha

Martin Woodward

Syeda F Y Haque

Paert Peterson

Annamari Ranki

Oliver Nussbaumer

Part Peterson

Edward Stuart

Steffen Meyer

Philip Vlaicu

Richard Woolf

Gunter Bauer

Michael Girardi

Karsten Henco

Richard L Edelson

Natalie Mount

Maria Luisa Iannitto

Justin Duckworth

Richard Esmond Beatson

Robert E Tigelaar

Raj Mehta

Günter Bauer

Pierre Vantourout

Oxana Polyakova

Robert Tigelaar

Iva Zlatareva

Robin John Campbell Dart

Adam Laing

Daisy Melandri

Richard Beatson

Richard Edelson

Pärt Peterson

Natalie Prescott

Syeda F Haque

The present invention provides methods of expanding γδ T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded γδ T cells and methods of using the expanded γδ T cells (e.g., a part of an adoptive T cell therapy).

Expansion of γδ T cells, compositions, and methods of use thereof

The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.

Method for obtaining globally activated monocytes

Protein constructs comprising a BTNL3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

BTNL3/8 targeting constructs for delivery of payloads

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-α antibodies

The present invention provides methods of expanding &#x3b3;&#x3b4; T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded &#x3b3;&#x3b4; T cells and methods of using the expanded &#x3b3;&#x3b4; T cells (e.g., apart of an adoptive T cell therapy).

Expansion of &#x3b3;&#x3b4; T cells, compositions, and methods of use thereof

This invention relates to the expansion of non-haematopoietic tissue-resident &#x3b3;&#x3b4; T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or interleukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident &#x3b3;&#x3b4; T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident &#x3b3;&#x3b4; T cells and uses thereof.

Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells

Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-&#x3b1; antibodies as well as IFN-&#x3b1; binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-&#x3b1; antibodies

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.

Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F

Nucleic acid molecules encoding monoclonal antibodies specific for IL-22

Human anti-IL-32 antibodies and methods of making and using the same

Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.

Method of isolating human antibodies

Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F

Growing community of inventors

Kent, United Kingdom

Adrian Hayday